Globus Medical's chart formed a hammer candlestick following a pullback, a pattern often signaling a potential reversal when support holds near session lows. The pattern suggests buyers stepped in after testing lower price levels, improving near-term bullish prospects.

Over the past month, Wall Street analysts have collectively raised 2026 EPS forecasts for Globus Medical, reflecting growing confidence in the firm’s margin resilience and recurring revenue strength. Upward revisions point to an expectation of stronger profitability driven by increased procedure volumes and product adoption.

The company currently offers a 4.9% earnings yield, well above the industry’s negative 0.7% average, and its shares have rallied 15.5% over the last year. With a Zacks Rank #1 strong buy designation, Globus Medical is positioned as a high-conviction pick based on attractive valuation and momentum factors.